IMPORTANCE Within 10 years after breast cancer diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC). Randomized trials have found that therapy including tamoxifen citrate and aromatase inhibitors (AIs) reduces CBC risk. But little is known about the magnitude and duration of protective associations within the context of real-world clinical management settings, where varying durations of and gaps in treatment are common.
A n increasing incidence of estrogen receptor (ER)-positive breast cancer in the United States in concert with the aging population and improved survival have resulted in a greater number of women at risk of developing second primary contralateral breast cancer (CBC). 1 The 10-year cumulative incidence of CBC is approximately 5%. 2 Randomized clinical trials have consistently demonstrated that tamoxifen citrate therapy reduces risk of primary cancer recurrence, improves survival, and decreases CBC risk.
3,4 An
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) pooled analysis of 20 trials examining long-term effects of 5 years of adjuvant tamoxifen therapy vs no tamoxifen use found an absolute reduction in CBC at 15 years of 3.2% among women whose initial diagnoses were ER positive, while tamoxifen therapy did not significantly alter the CBC incidence among women with ER-negative primary tumors. 3 Amassing trial data also indicate lower CBC risk with aromatase inhibitor (AI) use.
5,6
Despite strong evidence from trials, little is known about the magnitude and duration of protective associations within real-world treatment scenarios, where varying durations of and gaps in treatment are common. Observational studies 7-17 have reported marked reductions in CBC risk with use of tamoxifen or other unspecified endocrine therapies; however, most studies 7-12,14-17 have not directly examined therapy duration and the persistence of effects. Furthermore, observational studies 9, 12 have offered conflicting evidence as to whether associations differ according to the ER status of the CBC, and none have reported on the association between AI therapy and CBC risk.
We undertook an investigation of the association of adjuvant tamoxifen therapy and AI use with CBC risk in a cohort of women diagnosed as having invasive breast cancer within the Kaiser Permanente health care plan. This setting offers several advantages for studying these associations, including longterm systematic follow-up of a large number of patients with breast cancer with electronic prescription records, facilitating characterization of the persistence of associations of varying treatment durations, accounting for treatment gaps.
Methods

Study Population and Data Collection
We developed a retrospective cohort of patients (n = 8308) diagnosed as having a first primary unilateral invasive breast cancer at Kaiser Permanente Northwest Center for Health Research (Oregon) (4665 between January 1, 1990, and December 31, 2008) or Kaiser Permanente Institute for Health Research (Colorado) (3643 between January 1, 1994, and December 31, 2008) who survived and remained at CBC risk for at least 1 year. Data were analyzed from 1 year after diagnosis of the first breast cancer through the earliest of the following events: CBC diagnosis, other second cancer diagnosis, death, last tumor registry follow-up, exit from the Kaiser Permanente health care plan, or end of the study follow-up (December 
Exposure and Outcome Assessment
Treatment with tamoxifen, AIs, other hormonal agents, chemotherapeutic agents, and radiotherapy was obtained from electronic Kaiser Permanente prescription and medical records. Treatment courses were defined separately for tamoxifen and AIs and consisted of therapy without a gap in prescription coverage of at least 90 days. Women were considered users of adjuvant endocrine therapy if they had accumulated at least 90 days of therapy during any one treatment course after the first primary cancer diagnosis. Because of the recent introduction of AI therapy in this cohort, we assessed ever use but could not yet evaluate its recency or duration. Current tamoxifen use was defined as tamoxifen therapy within the past 30 days, whereas former use was defined as at least 30 days. Time since the last tamoxifen use was calculated from the end of the last tamoxifen course during the follow-up period, and 15.4% (601 of 3900) of patients treated with tamoxifen had at least 2 courses. 
Statistical Analysis
We used multivariable Poisson regression models to estimate relative risks (RRs) and 95% CIs for CBC risk associated with
Key Points
Question What is the association between adjuvant tamoxifen citrate and aromatase inhibitor therapy and contralateral breast cancer (CBC) risk within a general community setting?
Findings In this cohort study of 7541 patients with invasive breast cancer in a general community health care plan, tamoxifen therapy was significantly associated with reduced CBC risk during treatment, and risk decreased as tamoxifen therapy duration increased. Protective associations persisted at least 5 years after stopping tamoxifen therapy, and aromatase inhibitor use without tamoxifen therapy was associated with reduced CBC risk.
Meaning If adjuvant endocrine therapy is indicated for breast cancer treatment, women should be encouraged to complete the full course. Adjuvant tamoxifen use and AI therapy were treated as timedependent exposures, assessed using electronic prescription records. We evaluated risk in relation to a combination of tamoxifen therapy duration in years (continuous variable for log linear trend) and time since the last use (ie, current use and former use, with <3 years, 3 to <5 years, and ≥5 years since the last use), with the reference group defined as those who had never used tamoxifen or used tamoxifen for less than 90 days. Among former tamoxifen users, we also assessed risk in relation to categories of tamoxifen therapy duration of 90 days to less than 1 year, 1 year to less than 4 years, and at least 4 years using cut points based on the cohort distribution of the cumulative tamoxifen exposure. Sensitivity analyses evaluating CBC risk associated with the first tamoxifen course yielded similar results. Poisson regression models were stratified by covariates that we had identified a priori, including study site, age (<40, 40-49, 50-59, 60-69, or ≥70 years) and American Joint Committee on Cancer stage (I, II, III, or unknown) at diagnosis, ER status of the initial tumor (positive, negative, or unknown or indeterminate), time since the initial breast cancer in yearly categories up to 15 years or more, and, to account for potential cohort effects, diagnosis year (1990-1994, 1995-1999, 2000-2004, or 2005-2008) . We also adjusted models simultaneously for AI use (with or without tamoxifen therapy), chemotherapy with an alkylating agent, and radiotherapy. Because body mass index was not associated with tamoxifen therapy duration, it was not used in the adjustments.
In subgroup analyses, we evaluated associations by the ER status and age (<50 vs ≥50 years, a proxy for menopausal status) at diagnosis of the initial breast cancer. We also examined risk according to the ER status of the CBC. Among women surviving at least 5 years after a diagnosis of ER-positive breast cancer, we estimated the cumulative incidence of CBC according to tamoxifen therapy duration (no tamoxifen therapy, tamoxifen therapy duration of <4 years [the median duration], and tamoxifen therapy duration of ≥4 years), accounting for death and diagnosis of other second cancers as competing risks. 18 P < .05 was considered statistically significant. All tests of significance were 2-tailed. Analyses were performed using a software program (Epicure, version 2.10; HiroSoft International Corporation).
19
Results
Patient Characteristics Associated With CBC and Adjuvant Tamoxifen Therapy
The median age of the cohort at the initial breast cancer diagnosis was 60.6 years (age range, 24.9-84.9 years). Women were predominantly (92. In current users, the RR per year of tamoxifen use was 0.76 (95% CI, 0.64-0.89) ( Table) , with an estimated 66% (RR, 0.34; 95% CI, 0.29-0.40) RR reduction for 4 years of use compared with nonusers. Risk reductions were slightly smaller for past users but were still significant at least 5 years after stopping tamoxifen therapy (RR per year of use, 0.85; 95% CI, 0.71-0.995).
During the course of the study, 1929 patients (25.6%) received AIs (typically anastrozole or less frequently letrozole), with increasing use in more recent periods. Aromatase inhibitors taken with (n = 963) and without (n = 966) tamoxifen were used for median durations of 2.2 years (range, 0.3-10.2 years) and 2.9 years (range, 0.3-9.5 years), respectively. In addition, AI use without tamoxifen therapy was associated with reduced CBC risk (RR for AI users compared with nonusers, 0.48; 95% CI, 0.22-0.97) (10 diagnosed CBC cases) (Table) . Our study did not have sufficient statistical power to evaluate these risks in more detail. 
Subgroup Analyses by the ER Status of the Primary and CBCs
Among women whose first cancer was ER positive (n = 5951), findings were consistent with those of the overall cohort (Table) . Likewise, when considering the ER status of the subsequent CBC, risk of ER-positive CBC decreased significantly with increasing years of tamoxifen therapy duration among current users (RR per year of use, 0.68; 95% CI, 0.54-0.84) and among former users with less than 5 years since the last use compared with nonusers (RR per year of use in those with <3 years since the last use, 0.79; 95% CI, 0.67-0.91 and RR per year of use in those with 3 to <5 years since the last use, 0.83; 95% CI, 0.70-0.98). Among women whose primary cancer was ER positive, 31 were subsequently diagnosed as having ER-negative CBC. Although based on small numbers, there was little indication that tamoxifen therapy reduced ER-negative CBC risk when evaluated using tamoxifen therapy duration or when tamoxifen users were compared with nonusers (RR, 1.06; 95% CI, 0.41-3.10). Among women whose first primary cancer was ER negative (n = 1236), 186 (15.0%) used endocrine therapy, for which no clear associations were observed. Twenty-five of the CBCs were ER positive, and 13 were ER negative. Among patients with a first ER-negative cancer, tamoxifen therapy was not associated with reduced risk even of ER-positive CBC (RR, 1.97; 95% CI, 0.50-6.39) (4 diagnosed CBC cases); however, the numbers of CBCs diagnosed within treatment groups were small.
Subgroup Analyses by Age at the First Breast Cancer Diagnosis
In separate analyses by age at the initial diagnosis, findings among women who were 50 years or older at the initial diagnosis (eTable 4 in the Supplement) were similar to those observed in the overall cohort. Among women whose first breast cancer was diagnosed before age 50 years, risk reductions were similar for current and former users with less than 5 years since the last use but were based on only 53 CBC cases and not statistically significant. Figure 3 shows the estimated cumulative incidence of CBC adjusted for competing risks by tamoxifen use and duration among 3732 women who survived at least 5 years after a diagnosis of ER-positive first breast cancer. Of these patients, 2517 (67.4%) used tamoxifen, with a median duration of use of 4.2 years (range, 0.3-16.2 years). Patients who did not use tamoxifen had a 10-year cumulative incidence of CBC of 4.9% (95% CI, 3.3%-6.5%), whereas the incidence was lower among those taking tamoxifen for less than 4 years (3.3%; 95% CI, 2.1%-4.6%) and was lowest among those taking tamoxifen for at least 4 years (1.6%; 95% CI, 0.9%-2.3%). Among those surviving at least 5 years, tamoxifen use for at least 4 years was estimated to prevent 3 CBCs per 100 women by 10 years after an ERpositive first breast cancer. At 15 years after diagnosis, use of tamoxifen for at least 4 years was estimated to prevent 4 CBCs per 100 women.
Cumulative Incidence of CBC
Discussion
This retrospective analysis of more than 7500 US patients with invasive breast carcinoma treated in a general community health care plan suggests that adjuvant tamoxifen and AI therapies significantly reduce CBC risk. We have supplemented clinical trial data by testing associations in an unselected group of patients using electronic prescription records to accurately quantify risk reduction in CBC per year of adjuvant tamoxifen use and estimating the persistence of therapeutic effects in analyses, accounting for gaps in therapy and multiple treatment courses. We found that tamoxifen therapy protects against CBC when women are undergoing treatment and after treatment has ceased. Among former users, risk reduction was most apparent for those receiving tamoxifen for at least 4 years, with protective associations persisting during the first 5 years after stopping tamoxifen therapy. These associations were stronger among women whose first primary cancer was ER positive.
Risk reductions in CBC associated with at least 4 years of tamoxifen use in this observational cohort are consistent with those found in clinical trials of women randomized to 5 years of tamoxifen therapy. 20, 21 Whereas the standard intent-totreat analysis in trials only evaluates the prescribed treatment period, we directly evaluated the cumulative tamoxifen exposure over a wide range of durations (0.3-16.2 years) and observed progressive reductions in CBC risk with increasing duration. A systematic American Society of Clinical Oncology review concluded that women randomized to receive tamoxifen therapy either indefinitely or for 10 years compared with 5 years had lower CBC risk. 22 Less than 5% (377 of 7541) of patients in our cohort received cumulative tamoxifen therapy of 5 years or longer; however, our findings are still an extension Tamoxifen citrate therapy Never used <4 y use ≥4 y use
The data were adjusted for competing risks by tamoxifen therapy and duration among 3732 women who survived 5 or more years after being diagnosed as having an estrogen receptor-positive initial breast cancer.
beyond prior observational cohorts, which only evaluated risk estimates for tamoxifen therapy lasting at least 1 year.
8,9,13
As we have shown, the persistence of protective associations between adjuvant tamoxifen use and CBC risk likely depends on therapy duration, an issue not sufficiently addressed in prior observational studies.
7-12,14-17 In the Women's Environment, Cancer and Radiation Epidemiology (WECARE) casecontrol study, 7 significant protective effects of tamoxifen therapy on CBC risk persisted for 5 years after diagnosis, although therapy duration was not directly examined. Two nested case-control studies 8, 9 found that taking tamoxifen for at least 12 months was associated with decreased CBC risk, but the persistence of the effect was not reported. Cohort studies 10-17 have demonstrated substantial reductions in CBC risk with tamoxifen or other unspecified endocrine therapies. In the single cohort study 13 to have evaluated the persistence of effects in relation to tamoxifen therapy duration, no clear patterns emerged: that Danish study found that current but not former adjuvant tamoxifen therapy was associated with reduced CBC risk. The lack of effect among former users could be due to shorter tamoxifen therapy duration (median, 1.0-2.5 years) in that study relative to our US patient population. In contrast, findings from our observational study are consistent with a 2011 EBCTCG pooled analysis examining longterm effects of adjuvant tamoxifen therapy.
3 Similar to the EBCTCG's report of an absolute reduction of 3.2% in CBC at 15 years, we saw absolute CBC reductions of 3.3% at 10 years and 4.0% at 15 years for at least 4 years of tamoxifen therapy vs no tamoxifen use among ER-positive patients surviving 5 years or longer. Also consistent with the EBCTCG's pooled analysis, we found that tamoxifen therapy did not appear to lower the CBC incidence among women with ER-negative primary tumors, although our numbers were too small for precise evaluation. The agreement of our study with the EBCTCG's report regarding the effectiveness of tamoxifen therapy strengthens the evidence for a long-lasting reduction in CBC risk both within and outside of the clinical trial setting. Just as tamoxifen use has been shown to be most effective among women whose initial diagnosis is ER positive in our study and other studies, 9,12,23 tamoxifen therapy was particularly effective in reducing risk of ER-positive CBC. We and others 12 have also shown that tamoxifen use does not seem to significantly affect risk of ER-negative CBC; however, these findings conflict with those from a prior nested case-control study 9 that reported a 4.4-fold elevation in risk of ER-negative CBC (52 cases) associated with at least 5 years of adjuvant tamoxifen therapy. Although we had limited statistical power to evaluate risk of ERnegative CBC, the 95% CIs for tamoxifen-associated ERnegative CBC risk were not consistent with an increased risk of the magnitude reported previously. For decades, 5 years of tamoxifen use was the standard adjuvant therapy for patients with ER-positive tumors. 24 More recently, AIs have represented an alternate therapeutic option for ER-positive postmenopausal patients. 6, 25 In the 10-year analysis of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, 26 women randomized to receive anastrozole vs tamoxifen had significantly lower CBC risk. The recent introduction of AI therapy into clinical practice in our cohort precluded assessments of drug classes and the persistence of associations between varying AI therapy durations and CBC risk but will be the subject of future investigations.
In the United States, most observational investigations evaluating the effect of tamoxifen therapy on CBC risk have been designed as cross-sectional 7 or nested 8,9 case-control studies. A major strength of our retrospective cohort study is that it was conducted within a large, prepaid health care plan that provided all aspects of care, including cancer treatment and provision of prescription medications. Furthermore, the cohort design allowed for absolute risk estimation, which is essential for clinical decision making. Despite these advantages, our study had several limitations. Because our study was observational, patients who used endocrine therapy for long durations may differ in some manner compared with never or short-term users. While we adjusted for multiple patient and clinical characteristics, the possibility of residual or unmeasured confounding exists. American Society of Clinical Oncology guidelines 22 recommend that premenopausal or perimenopausal women who have hormone receptor-positive breast cancer should be offered adjuvant tamoxifen therapy. We could not fully evaluate this issue because we lacked data on the menopausal status in our cohort. Using age younger than 50 years as a proxy, we found that tamoxifen use was weakly associated with reduced CBC risk only among current and former users with less than 5 years since the last use. Current clinical guidelines recommend that postmenopausal women should be offered the choice of continuing tamoxifen use or switching to an AI for 10 years of adjuvant endocrine therapy. 22 Therefore, despite the older age of our cohort, our findings demonstrating significant reductions in CBC risk with adjuvant tamoxifen (and AI) therapy are still relevant within the context of contemporary clinical guidelines. Earlier reports of reduced CBC risk in adjuvant tamoxifen trials motivated its evaluation as a preventive agent and drew attention to the importance of the contralateral breast as a risk marker.
27,28 Therefore, our findings may have implications not only for women undergoing adjuvant therapy but also for breast cancer prevention. In a 2013 meta-analysis 29 of tamoxifen prevention trials, breast cancer incidence was significantly reduced within the 5-year active treatment period and the first 5 years after stopping tamoxifen therapy. Our analysis of patients treated with adjuvant tamoxifen during a 20-year follow-up period might provide some clues as to the persistence of protection in the chemopreventive setting.
As the decision to elect contralateral prophylactic mastectomy increases in popularity, despite the evidence suggesting no survival benefit over breast conservation, 5,30 data from a general community setting on the effects of adjuvant endocrine therapy on CBC risk, as well as on recurrence and death, will be important. Nonadherence to adjuvant endocrine therapy has been attributed to multiple factors, including adverse effects and financial constraints. 
